ASCO: A Time to Reflect and Learn
As conference season ramps up, it's a good time to reflect on the impact advances in pharma have on patients.
Mike Hennessy Jr.
President and CEO
of MJH Life Sciences
As I write this, it is three days before the ASCO Annual Meeting, the first in a series of conferences that arrive in rapid succession, such as the Consortium of Multiple Sclerosis Centers (CMSC), the American Society of Mass Spectrometry (ASMS), the American College of Rheumatology (ACR), and the many more conferences that the healthcare brands under MJH Life Sciences® cover. For the Pharmaceutical Executive® audience, we also look forward to BIO at the beginning of June and DIA at the end of the month, both in Boston this year.
However, it is ASCO that holds a special place at the heart of MJH. Our flagship oncology brands include OncLive®, Targeted Oncology™, CancerNetwork®, and CURE®. We also offer academic and community oncologists, nurses, patients, and all those involved with the cancer care journey with an unmatched selection of resources. These include our live educational events along with digital and print solutions that deliver the peer-to-peer education needed for improving patient outcomes. From video editorials to conference coverage, we independently produce content that combines objective facts and expert insights for the cancer care community.
Projects on the docket for MJH this year for ASCO are entering triple digits and include satellite symposia, panel discussions, and live workshops. We are renting studio space in Chicago, and all three of our studios will be running at full capacity as we complete close to 50 video projects across groups. Additionally, PER® will be hosting more than a dozen symposia at different hotels around the convention through the ASCO meeting.
On both sides of our business—healthcare and industry sciences—we continuously hear about those who have entered the field of oncology in a variety of roles to make an impact on those suffering from cancer. Whether it is a physician, a nurse, a pharma CEO, or clinical researcher, many are on the front lines with their stories that touch a tremendous amount of people with their compassion. We would like to thank them all for bringing us one step closer to a world without cancer.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
